Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CMS Cancels Part B Demo Before HHS Secretary-Designate Price Does

Executive Summary

President-elect Trump’s selection for HHS secretary, Rep. Tom Price, R-Ga., has been an outspoken critic of the proposed Medicare Part B drug demonstration project.

You may also be interested in...



Medicare's Part B Reform Proposal May Be Gaining Momentum; Congress Not Hearing Strong Protests

Muted stakeholder reactions may reflect Trump Administration efforts to address physician concerns in its Medicare Part B drug payment reform.

Can Medicare International Price Index Model Avoid Part B Demo Pitfalls?

Mandatory nature of demonstration might hamper progress of new model for changing Medicare Part B drug reimbursement, as it did when Obama Administration tried it.

Medicare Value-Based Contracting, Vendor Price Negotiation To Be Tested In Part B Demo

CMS using authority from previously abandoned competitive acquisition program; vendors may get ability to use formularies and apply utilization management techniques like prior authorization and step therapy.

Related Content

Topics

UsernamePublicRestriction

Register

PS119693

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel